Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.

The €50 million ($61 million) deal – in cash and stock – will give Exscientia ownership of a technology platform that takes patient samples and ... immuno-oncology candidate to be tested ...

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer ...

In a competitive labor market, highlight not only your technical skills but also adaptability and cultural fit.

The exams are being conducted across 7,842 centres in India and 26 countries abroad, with nearly 42 lakh students appearing ...

10 February 2025, Intramuros, Manila. – The environmental watchdog group EcoWaste Coalition is one with the Commission on ...

Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. Find out why I rate CADL stock ...

Predictive Oncology (POAI) provided an update highlighting new successes with its drug repurposing initiative. Using publicly available ...

ESET researchers have observed a cluster of North Korea-aligned activities that they named DeceptiveDevelopment and where its ...

Young men and young women are growing further apart romantically, and fewer of them worry about being alone these days.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...